Trial Overview
- The ATOMIC trial is a randomized, open-label, phase III multicenter study evaluating whether adding atezolizumab (anti-PD-L1 checkpoint inhibitor) to standard adjuvant mFOLFOX6 (fluorouracil, leucovorin, and oxaliplatin) improves outcomes after surgical resection of stage III dMMR colon cancer
- It enrolled 712 patients between approximately 2017 and 2023, with balanced baseline characteristics across arms
- Patients were randomized to:
- Experimental arm: mFOLFOX6 for 6 months plus atezolizumab (every 2 weeks) during chemo, followed by 6 more months of atezolizumab monotherapy
- Control arm: mFOLFOX6 alone for 6 months
- Primary endpoint: Disease-free survival (DFS); secondary endpoints: overall survival (OS) and safety/tolerability.
Key Findings
- Disease-Free Survival (DFS):
- At a median follow-up of ~37 months, the 3-year DFS was 86.4% in the atezolizumab-containing arm vs 76.6% with chemotherapy alone.
- This corresponds to a 50% reduction in the risk of recurrence or death (HR ≈ 0.50; highly statistically significant, P < 0.0001)
- Consistency: The benefit was observed across all major subgroups—including older patients, various tumor locations, and different clinical risk groups
- Safety:
- Grade ≥ 3 treatment-related adverse events occurred in 71.7% of the atezolizumab arm versus 62.1% in the chemotherapy-only arm
- Additional adverse events (e.g., fatigue, nausea, neutropenia) were more frequent but manageable, with no unexpected immune-related toxicities
Clinical Implications
- These results are practice-changing, establishing chemoimmunotherapy (atezolizumab plus mFOLFOX6) as a new standard of care for patients with resected stage III dMMR colon cancer
- The trial’s outcome is particularly significant for dMMR tumors, which historically show resistance to fluoropyrimidine chemotherapy yet exhibit high immunogenicity
- Further analyses are ongoing, including OS data maturation and biomarker work to identify patients most likely to benefit
